| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
SNAP-tag (an engineered protein tag derived from O⁶-alkylguanine-DNA alkyltransferase).
|
|---|---|
| ln Vitro |
Not applicable as PYBG-BODIPY is a fluorescent dye.
|
| ln Vivo |
Not applicable as PYBG-BODIPY is a fluorescent dye.
|
| Enzyme Assay |
Not applicable as PYBG-BODIPY is a fluorescent dye.
|
| Cell Assay |
Standard live-cell labeling protocol: Seed cells stably expressing SNAP-tag fusion protein (e.g., SNAP-tubulin, SNAP-H2B) in 8-well chambers or 96-well plates overnight. Wash cells twice with DMEM. Incubate cells with 0.5-5 uM PYBG-BODIPY in DMEM containing 10% FBS for 15-30 min at 37degC, 5% CO2. Wash cells three times with PBS. Add phenol red-free medium for imaging. Using fluorescence microscopy with appropriate filter sets (Ex/Em ~490/515 nm for BODIPY), capture high-resolution images to track protein localization, trafficking, and dynamics.
|
| Animal Protocol |
For in vivo imaging of SNAP-tag expressing tumors in mice: Prepare sterile solution of PYBG-BODIPY (100 uM in PBS or 5% glucose). Administer 50-100 uL via tail vein injection (dose ~2 mg/kg). Allow circulation for 1-2 hours to ensure complete labeling. Anesthetize mice with isoflurane. Perform whole-body fluorescence imaging using an IVIS Spectrum imaging system with 480 nm excitation and 520 nm emission filters. Euthanize mice, harvest tumors and major organs (liver, kidney, lung), and image ex vivo.
|
| ADME/Pharmacokinetics |
PYBG-BODIPY has molecular weight 732.59 g/mol. It is soluble in DMSO at up to 100 mg/mL. In plasma, the dye circulates primarily bound to serum albumin. Distribution to tissues expressing SNAP-tag is rapid (peak at 1-2 hours post-injection). Non-specifically bound dye is cleared via renal and hepatobiliary routes. The elimination half-life (t1/2) in mice is approximately 2-4 hours. BODIPY dyes generally exhibit good photostability and low quenching in biological environments.
|
| Toxicity/Toxicokinetics |
Based on related BODIPY dyes, PYBG-BODIPY exhibits low cytotoxicity at working concentrations (<10 uM) in vitro. In vivo studies at standard imaging doses (2-5 mg/kg, single injection) have not reported overt signs of toxicity. No long-term toxicity or genotoxicity data are available; standard laboratory safety precautions (gloves, lab coat) are recommended.
|
| References | |
| Additional Infomation |
PYBG-BODIPY is a state-of-the-art research tool for live-cell super-resolution microscopy and in vivo imaging of protein dynamics. It is licensed for research use only; not for diagnostic or therapeutic applications in humans. The high specificity and brightness of PYBG-BODIPY enable long-term tracking of SNAP-tagged proteins with minimal background, providing critical insights into cellular processes like vesicular transport and cytoskeletal remodeling.
|
| Molecular Formula |
C38H39BF2N10O3
|
|---|---|
| Molecular Weight |
732.59
|
| Exact Mass |
732.326
|
| CAS # |
2068027-79-0
|
| PubChem CID |
162642453
|
| Appearance |
Yellow to orange solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
54
|
| Complexity |
1380
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[B-]1(N2C(=CC(=C2C(=C3[N+]1=C(C=C3C)C)C4=CC=C(C=C4)OCCCN5C=C(N=N5)COCC6=CC=C(C=C6)COC7=NC(=NC8=C7NC=N8)N)C)C)(F)F
|
| InChi Key |
KCWYFUZODCBQMC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C38H39BF2N10O3/c1-23-16-25(3)50-34(23)32(35-24(2)17-26(4)51(35)39(50,40)41)29-10-12-31(13-11-29)53-15-5-14-49-18-30(47-48-49)21-52-19-27-6-8-28(9-7-27)20-54-37-33-36(44-22-43-33)45-38(42)46-37/h6-13,16-18,22H,5,14-15,19-21H2,1-4H3,(H3,42,43,44,45,46)
|
| Chemical Name |
6-[[4-[[1-[3-[4-(2,2-difluoro-4,6,10,12-tetramethyl-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-8-yl)phenoxy]propyl]triazol-4-yl]methoxymethyl]phenyl]methoxy]-7H-purin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (136.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3650 mL | 6.8251 mL | 13.6502 mL | |
| 5 mM | 0.2730 mL | 1.3650 mL | 2.7300 mL | |
| 10 mM | 0.1365 mL | 0.6825 mL | 1.3650 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
